378 related articles for article (PubMed ID: 34333002)
41. Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial.
Santamarina M; Carlson CJ
BMC Cardiovasc Disord; 2019 Mar; 19(1):60. PubMed ID: 30876392
[TBL] [Abstract][Full Text] [Related]
42. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
Ovalle F
Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
[TBL] [Abstract][Full Text] [Related]
43. Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox.
Green JB
Postgrad Med; 2014 May; 126(3):190-204. PubMed ID: 24918803
[TBL] [Abstract][Full Text] [Related]
44. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
[TBL] [Abstract][Full Text] [Related]
45. [New glucose-lowering drugs for reducing cardiovascular risk in patients with type2 diabetes mellitus].
Gorgojo-Martínez JJ
Hipertens Riesgo Vasc; 2019; 36(3):145-161. PubMed ID: 31079957
[TBL] [Abstract][Full Text] [Related]
46. The "Early Treatment" Approach Reducing Cardiovascular Risk in Patients with Type 2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique.
Russo G; Monami M; Perseghin G; Avogaro A; Perrone Filardi P; Senni M; Borghi C; Maggioni AP
Diabetes Ther; 2021 May; 12(5):1445-1461. PubMed ID: 33768493
[TBL] [Abstract][Full Text] [Related]
47. Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes.
Heuvelman VD; Van Raalte DH; Smits MM
Cardiovasc Res; 2020 Apr; 116(5):916-930. PubMed ID: 31825468
[TBL] [Abstract][Full Text] [Related]
48. Effects of sodium-glucose cotransporter-2 inhibitors on the cardiovascular and renal complications of type 2 diabetes.
Chilton RJ
Diabetes Obes Metab; 2020 Jan; 22(1):16-29. PubMed ID: 31407866
[TBL] [Abstract][Full Text] [Related]
49. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus.
Sharma A; Verma S
Can J Diabetes; 2020 Feb; 44(1):93-102. PubMed ID: 31882322
[TBL] [Abstract][Full Text] [Related]
50. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk.
Caussy C; Aubin A; Loomba R
Curr Diab Rep; 2021 Mar; 21(5):15. PubMed ID: 33742318
[TBL] [Abstract][Full Text] [Related]
51. Emerging glucose-lowering therapies: a guide for cardiologists.
Gulsin GS; Graham-Brown MPM; Davies MJ; McCann GP
Heart; 2020 Jan; 106(1):18-23. PubMed ID: 31551292
[TBL] [Abstract][Full Text] [Related]
52. Emerging Targets for Cardiovascular Disease Prevention in Diabetes.
Stitziel NO; Kanter JE; Bornfeldt KE
Trends Mol Med; 2020 Aug; 26(8):744-757. PubMed ID: 32423639
[TBL] [Abstract][Full Text] [Related]
53. Managing diabetes and liver disease association.
Hamed AE; Elsahar M; Elwan NM; El-Nakeep S; Naguib M; Soliman HH; Ahmed Aboubakr A; AbdelMaqsod A; Sedrak H; Assaad SN; Elwakil R; Esmat G; Salh S; Mostafa T; Mogawer S; Sadek SE; Saber MM; Ezelarab H; Mahmoud AA; Sultan S; El Kassas M; Kamal E; ElSayed NM; Moussa S
Arab J Gastroenterol; 2018 Dec; 19(4):166-179. PubMed ID: 30420265
[TBL] [Abstract][Full Text] [Related]
54. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
55. Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.
Doumas M; Imprialos Κ; Stavropoulos K; Reklou A; Sachinidis A; Athyros VG
Curr Pharm Des; 2018; 24(17):1879-1886. PubMed ID: 29865997
[TBL] [Abstract][Full Text] [Related]
56. All-cause mortality in patients with diabetes under glucagon-like peptide-1 agonists: A population-based, open cohort study.
Toulis KA; Hanif W; Saravanan P; Willis BH; Marshall T; Kumarendran B; Gokhale K; Ghosh S; Cheng KK; Narendran P; Thomas GN; Nirantharakumar K
Diabetes Metab; 2017 Jun; 43(3):211-216. PubMed ID: 28325589
[TBL] [Abstract][Full Text] [Related]
57. Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: A meta-analysis of cardiovascular outcome trials.
Singh AK; Singh R
Diabetes Res Clin Pract; 2021 Feb; 172():108648. PubMed ID: 33421444
[TBL] [Abstract][Full Text] [Related]
58. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
59. Impact of EMPA-REG OUTCOME
Naing S; Poliyedath A; Khandelwal S; Sigala T
Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
[TBL] [Abstract][Full Text] [Related]
60. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Kosiborod M; Lam CSP; Kohsaka S; Kim DJ; Karasik A; Shaw J; Tangri N; Goh SY; Thuresson M; Chen H; Surmont F; Hammar N; Fenici P;
J Am Coll Cardiol; 2018 Jun; 71(23):2628-2639. PubMed ID: 29540325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
